News | Clinical Decision Support | February 05, 2019

Planned software designed to sort and score cases automatically with Transpara deep learning technology from ScreenPoint Medical

Siemens Healthineers Syngo.Breast Care Adding AI-Based Decision Support

February 4, 2019 — Siemens Healthineers showcased the new planned artificial intelligence (AI)-based features with its mammography reading and reporting solution, syngo.Breast Care, at the 2018 Radiological Society of North America (RSNA) annual meeting, Nov. 25-30 in Chicago.1 These features are designed to provide physicians with interactive decision support.

AI features can help assist clinicians, particularly in cancer screening. A large number of mammograms are performed each day to screen for breast cancer, which means radiologists must accurately interpret hundreds of images daily. Additionally, the increased use of 3-D breast tomosynthesis adds to the number of images to be read. The new version of syngo.Breast Care is designed to give radiologists interactive clinical decision support.

AI-based algorithms are designed to help evaluate individual lesions and provide a system evaluation for 2-D mammograms or tomosynthesis. A peer-reviewed scientific study2 demonstrated increased sensitivity and specificity with the use of AI-based support.

Also, the planned software is designed to sort cases automatically and score those cases with a numerical value between 1 and 10. The case score is designed to take into account any existing lesions, microcalcifications and other abnormalities.   

syngo.Breast Care’s planned new SmartSort technology is designed for radiologists to rank exams according to their preferences based on these case scores. For example, critical cases can be moved immediately to the top to receive priority.

Siemens Healthineers collaborated with ScreenPoint Medical and plans to integrate interactive decision support in syngo.Breast Care. The company’s mammography reading software, Transpara, is based on deep learning and has been trained with over 1 million images.

Transpara received FDA 510(k) clearance for 2-D reading in late November.

For more information: www.usa.siemens.com/healthcare

References

1. Syngo.Breast Care VB40 - powered by Transpara, ScreenPoint Medical - is currently under development. It is not for sale in the U.S. Its future availability cannot be guaranteed.

2 Rodriguez-Ruiz A., Gubern-Merida A., Lang K., et al.: Detecting breast cancer in mammography: a deep learning-based computer system versus 101 radiologists (RSNA abstract 2018).


Related Content

News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
News | Digital Pathology

Feb. 11, 2026 — Leica Biosystems has announced the global launch of the Leica CM1950 Cryostat with DualEcoTec Cooling ...

Time February 11, 2026
arrow
Feature | Cardiac Imaging | Kyle Hardner

Advances in coronary CT angiography (CCTA) have reached the point where image quality and AI capabilities are creating ...

Time February 06, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Lung Imaging

Feb. 3, 2026 — RevealDx, a leader in the characterization of lung nodules, recently announced FDA clearance of RevealAI ...

Time February 04, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
Subscribe Now